Response of Relapsed/ Refractory Pediatric AML to Clad-AraC
Introduction: Relapsed/refractory (R/R) acute myeloid leukemia (AML) in children have poor outcome with no clear-cut guidelines on preferred regimen due to paucity of data in this cohort. Cladribine + Cytarabine (Clad-AraC) can be used in children with R/R AML. Methodology: Between January 2016 to December 2022, 74 children less than 15 years of age, with R/R AML received 119 cycles of Cladribine (9 mg/m2/dose for Day 1- 5) with Cytarabine (500mg/m2/dose Day 2-6). Complete remission (CR), event-free survival (EFS) and overall survival (OS) were analyzed. CR was defined
Authors
- Akanksha Chichra
- Gaurav Narula (ORCID: https://orcid.org/0000-0002-8539-295X)
- Chetan Dhamne (ORCID: https://orcid.org/0000-0002-3637-2880)
- Nirmalya Roy Moulik (ORCID: https://orcid.org/0000-0001-5650-3115)
- Shyam Srinivasan (ORCID: https://orcid.org/0000-0003-2587-9181)
- Rangasai Anirudh Neeli
- Shripad Banaval
Publication Details
- Journal
- OncoDaily Medical Journal
- Published
- 2025-01-01
- DOI
- https://doi.org/10.69690/odmj-018-0425-1648
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00